Last updated: February 17, 2026
Overview
NDC 10702-0150 refers to a specific formulation of a pharmaceutical product. Based on the National Drug Code (NDC), it is associated with Erythropoietin (Epoetin alfa), a recombinant DNA-derived human erythropoietin used to treat anemia associated with chronic kidney disease, chemotherapy, and certain other conditions.
Market Size
The erythropoietin market primarily serves patients with anemia related to chronic kidney disease (CKD), chemotherapy, and certain surgical procedures. The global erythropoietin market exceeded $10 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of approximately 6% from 2023 to 2030 ([1]).
Key market segments:
- CKD patients (approximately 30 million worldwide; 3 million in the U.S. alone)
- Chemotherapy-induced anemia
- Surgical and other indications
The U.S. accounts for roughly 60% of the global market, attributable to higher prevalence of CKD and greater drug reimbursement.
Competitive Landscape
Major players:
- Amgen (Epogen, Aranesp)
- Johnson & Johnson (Procrit)
- Pfizer (Retacrit)
These products dominate due to established manufacturing, broad indications, and reimbursement coverage. Biosimilars are entering the market, with notable approvals like Retacrit (Pfizer), reducing prices.
Pricing Dynamics
- Brand-name erythropoietins: Retail prices typically range from $300 to $600 per dose administered, depending on dosage and patient factors ([2]).
- Biosimilars: Price reductions of 15-30% relative to brand names are likely, with some biosimilars retailing around $200 to $400 per dose.
- Reimbursement and discounts: Settlements and negotiations with payers can reduce net prices further.
Price Trends & Projections
Current prices are stable but face pressure from biosimilar entry and policy interventions. Over the next five years, prices for the same formulations are expected to decline:
- Average wholesale price (AWP): Expected to decrease by 15-20%
- Net prices after discounts: Likely to decline by 20-25%, driven by biosimilar competition and cost-saving initiatives by healthcare providers.
The U.S. government initiatives targeting biosimilar adoption and reduction in prescribing of originator products influence pricing trajectories.
Regulatory & Policy Factors
- The biosimilar pathway under the Biologics Price Competition and Innovation Act (BPCIA) accelerates approval of biosimilar versions.
- Medicare reimbursement policies and formulary management will impact price stability.
- Anti-trust and patent litigation can delay biosimilar entry, affecting price stabilization timelines ([3]).
| Forecast Summary |
Year |
Estimated Price Range (per dose, USD) |
Key Drivers |
| 2023 |
$250–$600 |
Established brands, biosimilar entry |
| 2025 |
$200–$500 |
Increased biosimilar penetration |
| 2030 |
$150–$400 |
Mature biosimilar market, cost containment move |
Barriers to Market Entry & Price Suppression
- Manufacturing complexity of biologics
- Patent protections and litigation
- Physician and hospital prescribing habits
- Reimbursement policies favoring established products
Conclusion
The erythropoietin market for NDC 10702-0150 is mature, with stable demand driven by large patient populations. Price pressures due to biosimilars and policy shifts are expected to lower costs over the next decade.
Key Takeaways
- The market is valued at over $10 billion globally.
- US market accounts for roughly 60%, with high demand for CKD-related anemia treatments.
- Prices of erythropoietin drugs are decreasing due to biosimilar competition.
- Prices are projected to decline by 20-25% in the next five years.
- Regulatory environment and healthcare policies significantly influence market dynamics.
FAQs
1. What is the primary indication for NDC 10702-0150?
It is used to treat anemia associated with chronic kidney disease, chemotherapy, and surgical blood loss.
2. Who are the dominant manufacturers?
Amgen and Johnson & Johnson lead, with biosimilar entrants like Pfizer’s Retacrit entering the market.
3. How are biosimilars impacting pricing?
They reduce prices by 15-30%, increasing competition and prompting shifts toward cost containment.
4. What regulatory factors influence the market?
The BPCIA facilitates biosimilar approval, while reimbursement policies and patent litigations affect market entry and pricing.
5. What is the outlook for prices in the next five years?
Prices are expected to decline, with net prices dropping 20-25% due to biosimilar competition and policy measures.
References
- MarketWatch. "Global Erythropoietin Market Size, Share & Trends." 2022.
- GoodRx. "Erythropoietin Price Comparison." 2023.
- US Food and Drug Administration. “Biologics Price Competition and Innovation Act (BPCIA).” 2010.
